Clinical Trials Directory

Trials / Sponsors / Institut fuer Frauengesundheit

Institut fuer Frauengesundheit

Academic / Other · 10 registered clinical trials — 3 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingIMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
HR+/HER2- Early Breast Cancer
N/A2026-06-01
RecruitingPatient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
HR+/HER2- Early Breast Cancer
—2026-02-19
UnknownCLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer
Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma
—2023-03-10
RecruitingComprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Ad
Breast Cancer, Breast Neoplasms, Breast Neoplasm Female
Phase 42022-10-12
Active Not RecruitingComprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresec
Malignant Neoplasm of Breast, Breast Cancer
Phase 22022-07-30
UnknownNeoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
Breast Cancer, Breast Neoplasms, Breast Cancer Female
Phase 42021-07-11
UnknownAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer
Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic
Phase 42021-03-11
CompletedNeoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
Malignant Neoplasm of Breast
Phase 22018-03-23
UnknownEvaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)
is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.
Phase 42009-02-01
UnknownStudy on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cerv
Recurrent, Persistent or Metastasized Cervical Cancer
Phase 32006-09-01